Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
LifeMD (Nasdaq: LFMD) reported second quarter 2026 revenue of $47.3 million, within guidance of $47–$50 million but down from $49.0 million a year earlier. Adjusted EBITDA was a loss of about $3.5 million, versus positive $3.9 million in Q2 2025, though it improved roughly 21% sequentially. Gross margin expanded about 280 basis points year-over-year to approximately 89%, helped by lower shipping and fulfillment costs and scaling of the in-house pharmacy.
Active subscribers grew 20% to about 356,000, including roughly 108,000 Weight Management Program subscribers, and about 84% of revenue came from recurring subscriptions. LifeMD ended the quarter with $25.1 million in cash, no debt, and an undrawn $30 million revolver. The company revised 2026 guidance to revenue of $205.5–$212.5 million and adjusted EBITDA of -$6.0 million to breakeven, versus prior guidance of $220–$230 million and $12–$17 million, but continues to target a Q4 2026 annualized exit run rate of about $250 million of revenue and roughly $22 million of annualized adjusted EBITDA.
LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3 million, down from $49.0 million but within guidance, and an adjusted EBITDA loss of about $3.5 million, a ~21% sequential improvement. Gross margin expanded ~280 basis points year-over-year to ~89%, with about 84% of revenue from recurring subscriptions.
Active subscribers rose 20% year-over-year to ~356,000, including ~108,000 Weight Management Program subscribers, as ~95% of new weight management patients began branded GLP-1 therapies. LifeMD ended the quarter with $25.1 million in cash, no debt, and $30 million of undrawn revolver capacity. The company cut full-year 2026 guidance to $205.5–$212.5 million revenue and adjusted EBITDA of negative $6.0 million to breakeven, but still targets a Q4 2026 annualized exit run rate of about $250 million revenue and roughly $22 million of annualized adjusted EBITDA before estimated XYOSTED launch costs.
LifeMD (Nasdaq: LFMD) plans to report financial results for the three and six months ended June 30, 2026, after the U.S. market close on Wednesday, August 5, 2026. The company will host a conference call at 4:30 p.m. Eastern time to discuss its second quarter 2026 results.
Investors can join via toll-free dial-in at (800) 715-9871, international dial-in at +1 (646) 307-1963, using Conference ID 3616168 (“LifeMD, Inc. Second Quarter 2026 Results”). A live and archived webcast will be accessible via the specified link, and participants may also select a “Dial-Me In” option online.
LifeMD (Nasdaq: LFMD) declared a quarterly cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend is $0.5546875 per share, payable on July 15, 2026, to shareholders of record as of July 3, 2026.
LifeMD (Nasdaq: LFMD) announced an exclusive telehealth co-marketing collaboration with Halozyme’s Antares Pharma to launch a direct-to-patient, self-pay program for XYOSTED (testosterone enanthate) injection in July 2026.
The program will initially operate in 37 states, offering virtual evaluation, lab-based diagnosis, and home delivery of the once-weekly, FDA-approved testosterone auto-injector for about $249 per month, including medication and clinical care without insurance.
LifeMD (Nasdaq: LFMD) appointed Umesh Sripad as Chief Technology Officer, effective immediately. He will lead technology strategy, platform transformation, AI enablement, cybersecurity, data infrastructure, and scalability initiatives as LifeMD expands its direct-to-patient telehealth platform.
As an employment inducement, Sripad will receive 150,000 restricted stock units with service- and performance-based vesting.
LifeMD (Nasdaq: LFMD) announced that management will participate in two investor conferences in May 2026: the LD Micro Invitational XVI in Los Angeles and the B. Riley Securities 26th Annual Investor Conference in Marina del Rey, including presentations and one-on-one investor meetings.
LifeMD (NASDAQ: LFMD) reported Q1 2026 revenue of $50.2 million and an adjusted EBITDA loss of $4.5 million, in line with guidance. Gross margin expanded ~420 bps to 88%. Active subscribers rose 26% to ~365,000 with the largest quarterly net adds in company history (~42,000). Cash totaled $34.5 million with no debt. The company affirmed full-year 2026 guidance of $220M–$230M revenue and $12M–$17M adjusted EBITDA, and expects annualized run-rate revenue >$250M by Q4 2026.
LifeMD (Nasdaq: LFMD) will report first quarter 2026 financial results for the period ended March 31, 2026, after market close on May 6, 2026. A conference call and webcast will begin at 4:30 p.m. Eastern that day; dial‑in numbers and a replay will be available.
The event includes a live and archived webcast and standard toll‑free and international dial‑in access for investors and analysts.
LifeMD (Nasdaq: LFMD) announced it is now offering Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) through its weight management program via an integration with LillyDirect. The FDA approved Foundayo on April 1, 2026.
Foundayo is available to eligible patients with a starting self-pay price of $149/month, commercial patients may pay as little as $25/month with a Lilly savings card, and Medicare coverage is anticipated July 2026. LifeMD says the addition expands its branded GLP-1 offerings and supports virtual, clinically guided weight-management services.